Testosterone skin patch boosts sexual desire in women

PROCTER & GAMBLE Co yesterday moved a step closer to becoming the first company with a drug on the market to treat sexual dysfunction in women after releasing data from a late-stage clinical trial that backs up previous findings.

The testosterone skin patch, to be called Intrinsa, significantly improved sexual desire and satisfaction in women whose ovaries had previously been removed.

Although the company declined to discuss when it would file its new drug application with the Food and Drug Administration, P&G spokeswoman Mary Johnson said if approved they hope to have Intrinsa available by prescription sometime next year.